Tinjauan atas Angiotensin Receptor Blocker Generasi Baru
| Main Author: | Cherub, Jane |
|---|---|
| Format: | Article info application/pdf eJournal |
| Bahasa: | eng |
| Terbitan: |
PT. Kalbe Farma Tbk
, 2020
|
| Online Access: |
http://www.cdkjournal.com/index.php/CDK/article/view/1088 http://www.cdkjournal.com/index.php/CDK/article/view/1088/801 |
Daftar Isi:
- Angiotensin receptor blockers (ARB) yang bekerja menghambat reseptor AngII-AT1 secara selektif direkomendasikan sebagai agen antihipertensi lini pertama. Saat ini terdapat 8 varian ARB di pasaran. Selain efek antagonisasinya terhadap AT1, ARB generasi baru memiliki mekanisme tambahan yang dapat menarget hipertensi, penyakit kardiovaskular, dan diabetes. ARB generasi baru juga memblokir reseptor endotelin, berfungsi sebagai donor oksida nitrat, menghambat aktivitas neprilysin dan meningkatkan kadar peptida natriuretik, atau merangsang peroxisome proliferatoractivated receptor gamma (PPARĪ³). ARB generasi baru dapat memiliki nilai klinis dan manfaat terapeutik lebih besar daripada hanya melalui penghambatan reseptor AT1.Angiotensin receptor blockers (ARBs) works by selectively blocking AngII-AT1 receptors; it is recommended as a first-line antihypertensive agent. Currently there are 8 variants of ARB in the market. In addition to its AT1 antagonist effect, new generation of ARB can have additional mechanisms on hypertension, cardiovascular disease and diabetes. New generation ARBs also block endothelial receptors, as nitric oxide donors, inhibit neprilysin activity and increase levels of natriuretic peptides, or stimulate peroxisome proliferator-activated gamma receptors (PPARĪ³). New generation of ARBs can have considerable clinical value and provide greater therapeutic benefits.